Literature DB >> 2066349

Progress and challenges in the global effort against cancer.

S Broder.   

Abstract

The new decade has given birth to a large number of new concepts in our approach to cancer. The progress in molecular technology that occurred in the 1980's is being transferred in the 1990's to the bedside. The practical clinical application of basic science innovations is aimed at prevention and curative treatment of cancer in all of its forms, and is becoming a central theme of cancer therapeutics. The progress to date reflects a climate that fosters a unity of basic and clinical investigations, for example, where an understanding of tumor genetics or molecular immunoregulation can translate into an innovative clinical approach such as gene transfer therapy. The challenges that we face in this new decade arise in part from progress in certain areas, such as the discovery of natural products that have important antitumor activity but a limited source, or the increasing incidence in AIDS-related lymphomas that has come about from antiretroviral therapy-induced prolongation of survival for AIDS patients. There are critical challenges from a lack of progress in other areas, as well. The challenge of developing curative therapies is surpassed by the need to prevent those cancers before they arise. The challenge of prevention, as exemplified by the link between lung cancer and smoking, is of paramount importance. The ultimate challenge placed before the global oncology community is to ensure that the fruits of modern technology are available to all who need them.

Entities:  

Mesh:

Year:  1991        PMID: 2066349     DOI: 10.1007/BF01630710

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  49 in total

Review 1.  Role of human immunodeficiency virus type 1 and other viruses in malignancies associated with acquired immunodeficiency disease syndrome.

Authors:  K J Cremer; S B Spring; J Gruber
Journal:  J Natl Cancer Inst       Date:  1990-06-20       Impact factor: 13.506

2.  Tumors arising in organ transplant recipients.

Authors:  I Penn
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

3.  Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man.

Authors:  A Kasid; S Morecki; P Aebersold; K Cornetta; K Culver; S Freeman; E Director; M T Lotze; R M Blaese; W F Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

4.  Ataxia-telangiectasis: a multisystem hereditary disease with immunodeficiency, impaired organ maturation, x-ray hypersensitivity, and a high incidence of neoplasia.

Authors:  T A Waldmann; J Misiti; D L Nelson; K H Kraemer
Journal:  Ann Intern Med       Date:  1983-09       Impact factor: 25.391

5.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

Authors:  K W Moore; P Vieira; D F Fiorentino; M L Trounstine; T A Khan; T R Mosmann
Journal:  Science       Date:  1990-06-08       Impact factor: 47.728

6.  The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours.

Authors:  J M Varley; J Armour; J E Swallow; A J Jeffreys; B A Ponder; A T'Ang; Y K Fung; W J Brammar; R A Walker
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

7.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

8.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.

Authors:  J W Harbour; S L Lai; J Whang-Peng; A F Gazdar; J D Minna; F J Kaye
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

9.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors:  A Belldegrun; L M Muul; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

Review 10.  Taxol: a novel investigational antimicrotubule agent.

Authors:  E K Rowinsky; L A Cazenave; R C Donehower
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.